5. Medtech is mature, but there is still optimism.
[Image from unsplash.com]
There are many disease states do not have a viable treatment or therapy, so there are still a lot of opportunities. In fact, the economic pressure might do well in spurring innovation. And even though the U.S. investment market has shifted to biotech, other countries with capital to spend, such as those in Asia, are still looking at medical devices.